General
Johnson & Johnson single-dose vaccine shown to be effective against COVID-19
Johnson & Johnson’s (J&J) vaccine candidate appears to protect against COVID-19 with just one shot of the dose.
Key points:
- Johnson & Johnson says trial results show its one-shot vaccine is 66 per cent effective against COVID-19
- While promising, it is still behind many rivals who are using a two-shot vaccine
- The company says trying to create a vaccine which requires one shot is worthwhile as the virus continues to spread
The single-shot option is not as strong as some of its two-shot rivals, however it could be potentially helpful for a world in dire need of more doses.
J&J said on Friday that in the US and seven other countries, the single-shot vaccine was 66 per cent per cent effective overall at preventing moderate to severe illness.
The…
Continue Reading
-
Business23 hours agoWhy these are 2 of the most exciting ASX 300 shares to buy right now
-
Noosa News22 hours agoInside the illegal tobacco trade —secret rooms, fire bombings and bags full of cash
-
Business20 hours agoThese ASX 200 shares could rise 15% to 20%
-
Business19 hours agoEvery ASX 200 sector closed in the red last week. Here’s why